Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Systemic Corticosteroid Usage in Stage 4 Pulmonary Sarcoidosis Could Offer Little Benefit, Pose Significant Health Risk

Josna Haritha, MD, MPH, Derick N. Jenkins, MD, & Manpreet Malik, MBBS  |  Issue: November 2016  |  November 16, 2016

Depending on stage, severity and rate of progression of disease, systemic corticosteroids are commonly used to treat pulmonary sarcoidosis. However, a review of the literature suggests they have limited usefulness in advanced stage IV pulmonary sarcoidosis. Once sarcoidosis has advanced to this degree, steroid use may unnecessarily expose a patient to life-threatening complications, as demonstrated in this report.

Case Presentation

A 41-year-old man presented to the emergency department with massive hemoptysis that resulted in a cardiac arrest. With emergent resuscitation, return of spontaneous circulation was achieved, and the patient was intubated for hypoxic respiratory failure, requiring mechanical ventilation. His medical history was significant for a 10-year history of pulmonary sarcoidosis and steroid-induced diabetes. His medication regimen included prednisone, 20 mg twice daily, which he had been taking for the preceding four months.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A chest CT (see figures below and on p. 24) demonstrated advanced, Stage IV pulmonary sarcoidosis with significant architectural distortion related to multiple mycetomas visualized in the left upper lobe, right middle lobe and right upper lobe, and markedly distorted bronchiectatic airways connecting to the dominant mycetomas. Pulmonary angiography localized bleeding from both bronchial arteries, as well as a branch of the right bronchial artery, which was supplying the right upper lobe. Interventional radiology performed successful particle embolization of the culprit arteries.

Pulmonary hypertension is commonly seen in Stage IV sarcoidosis, & steroids have not been shown to result in a significant hemodynamic response in this subset of patients. Thus, the role of steroids in advanced stage IV disease is limited.

Laboratory studies were significant for a positive Platelia (ELISA for Aspergillus) of 5.27 (index ≥0.5 is positive) and Fungitell assay greater than 500 pg/mL (glucan values ≥80 pg/mL are positive), confirming aspergillosis. Voriconazole therapy was initiated, and the patient was discharged home with a steroid taper schedule. After further evaluation, he underwent lung transplantation two months later.

An axial CT view demonstrating a large mycetoma in the right upper lobe and a left upper lobe cavitating lung lesion.

An axial CT view demonstrating a large mycetoma in the right upper lobe and a left upper lobe cavitating lung lesion.

An axial CT view demonstrating a mycetoma in the right lower lobe.

An axial CT view demonstrating a mycetoma in the right lower lobe.

An axial CT view demonstrating a mycetoma in the right middle lobe.

An axial CT view demonstrating a mycetoma in the right middle lobe.

Discussion

Asymptomatic pulmonary sarcoidosis, regardless of stage, does not require the initiation of steroid therapy, but rather should be monitored for clinical progression. Steroids should be considered in patients with significant symptoms (e.g., cough, dyspnea, hemoptysis), worsening radiographic findings and worsening pulmonary function tests.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:ClinicalCorticosteroidshealth riskhemoptysishypertensionmycetomaspatient carepulmonary sarcoidosisResearchSteroidtherapyTreatmentusage

Related Articles

    Case Report: Pulmonary Sarcoid-Like Reaction in Patient Treated with Etanercept

    April 15, 2022

    Sarcoidosis is a multisystem disease characterized by noncaseating granulomas in affected tissues, mostly involving the lungs and lymph nodes.1,2 The etiology of sarcoidosis remains unknown but is thought to be due to an inflammatory response to an antigen exposure in genetically predisposed individuals.1 Tumor necrosis factor-α (TNF‑α), a pro-inflammatory cytokine, plays an essential role in…

    Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis

    June 1, 2021

    An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.

    Case Report: Perplexing Pulmonary Nodules

    March 14, 2022

    Pulmonary nodules are com­mon; most are benign, but the differential diagnosis is broad and includes life-threatening possibilities.1 Our patient is a former smoker who has a history of a complex autoimmune disease and multiple pulmonary nodules. This case was challenging, but clinical, radiographic and histologic clues helped lead to the correct diagnosis. Case Presentation The…

    Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors

    November 1, 2013

    Two patients with psoriatic arthritis treated with TNF-alpha inhibitor therapy develop the multisystem disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences